Canada markets open in 7 hours 55 minutes

Certara, Inc. (CERT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.80-0.06 (-0.25%)
At close: 04:00PM EDT
23.80 0.00 (0.00%)
After hours: 04:08PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close23.86
Bid0.00 x 800
Ask0.00 x 800
Day's Range23.58 - 24.14
52 Week Range10.60 - 24.83
Avg. Volume1,310,895
Market Cap3.805B
Beta (5Y Monthly)1.45
PE Ratio (TTM)264.44
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    A.I. Coming to Certara’s D360 Scientific Informatics Software

    New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses.PRINCETON, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, is adding deep learning capabilities to D360, a leading scientific informatics software platform. The addition of novel A.I. will enable discovery scientists to integrate multiple structured and unstructured data sources and substantia

  • GlobeNewswire

    Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types

    Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studiesPRINCETON, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 22, which includes new capabilities and updated features to the Company’s population-based modeling and simulation platform. The Simcyp Simulator is the pharmaceutical industry’s most sophisticated

  • GlobeNewswire

    Certara Reports Fourth Quarter and Full Year 2022 Financial Results

    Annual Revenue Grows 17% on a Reported Basis and 20% at Constant CurrencyPRINCETON, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2022 and issued guidance for 2023. Fourth Quarter Highlights: Revenue was $86.6 million, compared to $75.3 million in the fourth quarter of 2021, representing growth of 15% over the fourth quarter of 2021 on a reported basis and 18% a